Galapagos to be included in Amsterdam Midcap Index
(Thomson Reuters ONE) -
Mechelen, Belgium; 6 March 2015 - Galapagos NV (Euronext: GLPG) announces that
Euronext will include Galapagos in the Amsterdam Midcap Index, following
Euronext's annual review of the AEX(®), AMX(®) and AScX(®) indices, effective
23 March 2015.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other indications. In
the field of inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib. Filgotinib is an
orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in Phase 2B
studies in RA and in Phase 2 in Crohn's disease. GLPG1205, a first-in-class
inhibitor of GPR84, is currently being tested in a Phase 2 proof-of-concept
trial in ulcerative colitis patients. GLPG1690 is a compound that targets
pulmonary diseases and is currently in a Phase 1 trial. AbbVie and Galapagos
also signed a collaboration agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR gene. Potentiator
GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-
clinical candidate stage. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements concerning the safety and efficacy of filgotinib and the
expected timing of the release of topline 12-week results from the DARWIN 1 and
2 trials and the expected timing and announcement of topline 24-week results
from the DARWIN 1 and 2 trials, expectations regarding the commercial potential
of our product candidates generally, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made through the
use of words or phrases such as "believes," "anticipates," "expects," "intends,"
"plans," "seeks," "estimates," "may," "will," "could," "stands to," "continues,"
"we believe," "we intend," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other factors
which might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially different from
any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Among the
factors that may result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product development
activities, regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of publication of
this document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based, unless required by law or
regulation.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1899948]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Glenmark Acquires Margurete Gold Project, SW British ColumbiaDatum: 06.03.2015 - 07:35 Uhr
Sprache: Deutsch
News-ID 376639
Anzahl Zeichen: 4895
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos to be included in Amsterdam Midcap Index"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
